Diligence memo · auto-generated · as of July 2, 2026

Neurolink, Inc.

Neurolink, Inc. looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Neurolink, Inc. operates in Biotechnology, based in San Antonio.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Neurolink, Inc. has raised $3.9M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).

Largest single filing: $2.3M on 2010-12-28.

Most recent recorded round closed around 2010-12-28.

Valuation (modeled)modeled

Provath models Neurolink, Inc. at approximately $100M (range $1.6M–$788M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.16× the median modeled value of Seed Biotechnology companies in 2010–2012 (151 peers) — value vs value, same stage and era. Within the normal band (116% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 3 months.

Last raise 15.5 yr ago; this sector typically re-raises about every 14 months.

Silent for over 3× the sector's normal cadence.

The last round stepped up 1.4× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 39% of Biotechnology peers (4293 compared).

Modeled value ranks above 59% of those peers.

Closest niche peers: Denali Medical II, Inc., Signum Biosciences, Inc., Health Elements, LLC, Nkt Therapeutics Inc, Surface Logix Inc.

Peoplefiled

3 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.